AI Article Synopsis
- Rats with prostate cancer were treated with either human serum albumin or a combination of human serum albumin and recombinant tumor necrosis factor (rTNF) through two different injection methods.
- Intratumoral (i.t.) administration of rTNF led to significantly longer survival rates and smaller tumors compared to untreated controls.
- Intraperitoneal (i.p.) injection of rTNF resulted in less significant survival improvements and intermediate tumor sizes.
Article Abstract
Copenhagen X Fischer F1 rats bearing palpable Dunning R3327 MAT-LyLu prostatic adenocarcinomas were treated by intraperitoneal (i.p.) or intratumor (i.t.) injection with either human serum albumin alone or in combination with recombinant tumor necrosis factor (rTNF). At intervals tumors were measured and survivals noted. A maximum tolerable dose and least toxic route of administration was then determined. Those treated i.t. with rTNF survived significantly longer and ultimately developed significantly smaller tumors than untreated controls. Those administered rTNF by the i.p. route had less significant increases in survival with intermediate final tumor sizes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KRAS oncogene-expressing tumor cells.
Transgenic Res
January 2025
Laboratory of Cell and Developmental Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague 4, Czech Republic.
Proto-oncogene KRAS, GTPase (KRAS) is one of the most intensively studied oncogenes in cancer research. Although several mouse models allow for regulated expression of mutant KRAS, selective isolation and analysis of transforming or tumor cells that produce the KRAS oncogene remains a challenge. In our study, we present a knock-in model of oncogenic variant KRAS that enables the "activation" of KRAS expression together with production of red fluorescent protein tdTomato.
View Article and Find Full Text PDFRAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Clin Cancer Res
December 2024
Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Purpose: The randomized GeparOla trial reported comparable pathological complete response (pCR) rates with neoadjuvant containing olaparib vs. carboplatin treatment. Here, we evaluate the association between functional homologous repair deficiency (HRD) by RAD51 foci and pCR, and the potential of improving patient selection by combining RAD51 and stromal tumor infiltrating lymphocytes (sTILs).
View Article and Find Full Text PDFAdalimumab is a recombinant human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha). It has become an important drug in the treatment of inflammatory bowel diseases (IBD), which do not respond to initial medical treatment. The case of a patient with ulcerative proctitis is presented, who developed acute pleuropericarditis, after starting treatment with Adalimumab.
View Article and Find Full Text PDFBackground: XPro1595 (XPro) is a brain-penetrant, recombinant protein variant of human tumor necrosis factor (TNF) rationally designed to selectively neutralize only the soluble, pro-inflammatory form of the cytokine (solTNF). An unbiased proteomic analysis of CSF samples from an open-label, phase-1b study (NCT03943264) in patients with Alzheimer's disease (AD) was conducted to assess for pharmacodynamic activity and disease-specific target engagement.
Method: Patients with AD (n = 20) were treated for 12-weeks with one of three doses of XPro: 0.
PUF60 Promotes Chemoresistance Through Drug Efflux and Reducing Apoptosis in Gastric Cancer.
Int J Med Sci
January 2025
Department of Gastrointestinal Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Chemotherapy resistance is a great challenge in the treatment of gastric cancer (GC), so it is urgent to explore the prognostic markers of chemoresistance. PUF60 (Poly (U)-binding splicing factor 60) is a nucleic acid-binding protein that has been shown to regulate transcription and link to tumorigenesis in various cancers. However, its biological role and function in chemotherapy resistance of GC is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!